Clinical trials: Priming
Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction
Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)
This bridging study is a randomized, double-blind, two arms parallel group, prospective intervention study. The primary objective of this study is to evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) using new Hepatitis B…
- Conditions
- Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction, Pertussis Vaccine Adverse Reaction, Haemophilus Influenzae Type B Vaccine Adverse Reaction
- Trial name
- NCT05482282
- Testing
- Recombinant Hepatitis B new Bulk vaccine, DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine, Recombinant Hepatitis B vaccine (Registered BioFarma)
- Where
- 3 sites in Indonesia
- Volunteers
- healthy volunteers welcome
- Sponsor
- PT Bio Farma
Safety, Immunogenicity
EMaBS TB Vaccine Study
The study will commence with a dose-escalation and age de-escalation study in healthy adults and adolescents from the previous Entebbe Mother and Baby Study (EMaBS) in Entebbe, Uganda, focusing on ChAdOx1 85A, to provide safety…
- Trial name
- NCT03681860
- Testing
- ChAdOx185A, MVA85A, BCG
- Where
- 2 sites in Uganda, United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating…
- Conditions
- Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
- Trial name
- NCT03091660
- Testing
- BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine
- Where
- 174 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- SWOG Cancer Research Network
Hib Disease, Hepatitis B
Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths
To assess the anti-PRP antibody response one month after vaccination in the groups receiving a fourth consecutive dose of two formulations of DTPw-HBV/Hib vaccine
- Conditions
- Hib Disease, Hepatitis B, Pertussis, Prophylaxis of Diphtheria
- Trial name
- NCT00158808
- Testing
- Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib
- Where
- Philippines
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Rubella
Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial
This is a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial. Age de-escalation will be based on a review of the safety data from the preceding cohort (adults for toddlers…
- Conditions
- Measles, Rubella, Vaccination, Healthy
- Trial name
- NCT04394689
- Testing
- Measles Rubella Vaccine (MRV-SC), MRV-MNP, PLA-MNP
- Where
- The Gambia
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Micron Biomedical, Inc
Hemorrhage
Albumin vs. Plasma for PEdiAtric pRiming Trial
This is a randomized controlled trial that compares two different priming composition (albumin vs. fresh frozen plasma) for extracorporeal circulation of pediatric patients under 10 kg of weight.
- Trial name
- APPEAR (NCT02738190)
- Testing
- Albumin, Fresh Frozen Plasma
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Policlinico S. Donato
Unilateral Cerebral Palsy
Multi Sensory Stimulation And Priming (MuSSAP) in Infants at Risk of Unilateral Cerebral Palsy
A pilot randomized clinical trial exploring the effect of a Multi Sensory Stimulation And Priming (MuSSAP) training on improving manual ability in infants at risk of developing unilateral Cerebral Palsy.
- Trial name
- MuSSAP (NCT05533476)
- Testing
- Multi Sensory Stimulation and Priming, Intensive Usual Care (Upper Limb)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sint Maartenskliniek
Viral Diseases
Identification of Viruses Associated With Diseases of Unknown Cause
This study will try to identify new or known viruses responsible for diseases or conditions of unknown cause. Viruses are an important cause of illness.
- Trial name
- NCT00359268
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Children in a Malaria Endemic Area
Infants in malaria-endemic regions of Africa are an important target for vaccination against malaria in view of the enormous disease burden of malaria in this population.
- Trial name
- NCT01450293
- Testing
- AdCh63 ME-TRAP, MVA ME-TRAP
- Where
- The Gambia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Myopia Progression
Prospective Research on the Intervention of Myoless2.0 Effectiveness (PRIME) in Pediatric Population
The Goal of the study is to evaluate the rate of myopia progression with open ring myopia control spectacle lens designs compared to a commercial peripheral plus myopia control spectacle lens (CML) in European children with…
- Trial name
- PRIME (NCT07394556)
- Testing
- myopia control lens
- Where
- 3 sites in Portugal, Spain and 1 more
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Indizen Optical Technologies, S.L.U.
Influenza
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
This is a Phase I, dose escalation study in healthy adolescents and children (6-17 years) to evaluate the safety, tolerability, and immunogenicity of a prime-boost regimen of the 2012/2013 seasonal influenza DNA vaccine (HA DNA)…
- Trial name
- NCT01609998
- Testing
- Seasonal Influenza DNA vaccine, TIV
- Where
- 5 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningococcal Disease
PRIME Follow up - Quadri Meningo Vacinees
A previous cohort of 93 clinical trial participants received quadrivalent meningococcal conjugate vaccine, which includes strains ACW and Y, in their teenage years.
- Trial name
- PRIMEfollowup (NCT02811120)
- Testing
- venepuncture only
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Public Health England
Streptococcus Pneumoniae
PCV10 Immunogenicity Study Nepal 2015
A single centre open-label, parallel group, randomised controlled trial, recruiting healthy Nepalese infants aged 40-60 days, who present to the immunisation clinic at Patan Hospital, Kathmandu, Nepal, randomised to receive a…
- Trial name
- NCT02385513
- Testing
- 10-valent pneumococcal conjugate vaccine
- Where
- United Kingdom
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Acute Myeloid Leukemia
Azacytidine Plus FLAG for Relapsed or Refractory AML
The purpose of this phase 2 study is to test the efficacy of azacytidine given prior to fludarabine, cytarabine, and G-CSF for the treatment of relapsed or refractory acute myeloid leukemia.
- Trial name
- NCT02275663
- Testing
- Azacytidine, Fludarabine, Cytarabine
- Where
- Saudi Arabia
- Volunteers
- 37 people
- Sponsor
- King Fahad Medical City
Cardiac Diseases, Stroke
DanceFit Prime: A Dance Based Physical Activity and Nutritional Intervention for Primary Care - A Feasibility Study
Regular physical activity improves physical and mental health and reduces the risk of heart disease, stroke, cancer, diabetes, obesity and premature death from any cause.
- Conditions
- Cardiac Diseases, Stroke, Diabetes Mellitus, Dementia
- Trial name
- DanceFit (NCT02159014)
- Testing
- Facilitated group-based aerobic dance, Online, video prompted, individual aerobic dance, Facilitated group-based nutritional intervention
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- North Essex Partnership NHS Foundation Trust
Diffuse Midline Glioma, Diffuse Midline High-grade Glioma
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine…
- Conditions
- Diffuse Midline Glioma, Diffuse Midline High-grade Glioma, Medulloblastoma, Ependymoma
- Trial name
- PRiME II (NCT06639607)
- Testing
- PEP-CMV vaccine, Tetanus booster, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 68 people
- Sponsor
- Washington University School of Medicine
Coronary Artery Disease
Evaluation of Effectiveness and Safety of XIENCE PRIME Stent (IRIS-PRIME)
The objective of this study is to evaluate effectiveness and safety of XIENCE PRIME stent in the "real world" daily practice as compared with other drug eluting stents (DESs)
- Trial name
- NCT01348399
- Where
- 29 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- Seung-Jung Park
Poliomyelitis, Vaccine Reaction
Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants
Eupolio is inactivated poliovirus vaccine (IPV). Major purpose of this study is to evaluate safety of Eupolio in 2,000 infants. In addition to the safety, long-term protection after completion of the three primary vaccinations…
- Trial name
- NCT05431933
- Testing
- Eupolio
- Where
- 10 sites in Philippines, Thailand
- Volunteers
- 2,001 people, healthy volunteers welcome
- Sponsor
- LG Chem
Phase 2, Radiotherapy-Induced Immune Priming
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
- Conditions
- Phase 2, Radiotherapy-Induced Immune Priming, Elranatamab, Relapsed Refractory Multiple Myeloma (RRMM)
- Trial name
- NCT07382739
- Testing
- Elranatamab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Clinical High Risk Syndrome for Psychosis
PRIME vs Usual Care for Clinical High Risk
The purpose of this study is to determine whether specialty care is superior to usual care in the treatment of patients at clinical high risk for psychosis.
- Trial name
- NCT02960451
- Testing
- PRIME care, Usual care
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Yale University